Dover to Expand Portfolio with Acquisition of Em-tec
The acquisition will expand Dover’s biopharma and hygienic applications capabilities by enhancing its portfolio of flow control technologies with flow rate sensors.
Dover, a manufacturing company based in Downers Grove, IL, and PSG, Dover's business unit, announced on March 18, 2020 that it is entering into a definitive agreement to acquire Em-tec GmbH, a designer and manufacturer of flow measurement devices based in Germany. Financial terms of the agreement were not disclosed.
According to a Dover press release, the acquisition will expand Dover’s biopharma and hygienic applications capabilities by enhancing its portfolio of flow control technologies with flow rate sensors.
“We are excited to bring together Em-tec’s flow measurement devices and PSG’s Quattroflow pump technology to expand our offering to our customers in biopharma and medical applications,” said Richard J. Tobin, Dover’s president and CEO, in the press release.
“We are excited to have the opportunity to integrate Em-tec’s flow technology with our PSG pumps post-acquisition to provide smarter solutions to our customers where critical flow control is paramount,” added Karl Buscher, president, PSG, in the press release.
The deal is expected to close during the second quarter of 2020.
Source: Dover
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
